CLAIMS

1. A therapeutic agent for chronic obstructive pulmonary disease comprising, as an active ingredient, at least one of a 7-aminoquinolinone derivative represented by the general formula (I):

$$R_5$$
 N
 O
 OR_2
 OR_3
 OR_2

wherein R_1 represents a hydrogen atom or an alkyl group; R_2 and R_3 each represents a group selected from a hydrogen atom, an acyl group, an alkyl group and an alkenyl group; and R_4 and R_5 each represents a group selected from a hydrogen atom, an acyl group, an alkyl group, an alkenyl group and an aralkyl group, and its physiologically acceptable salt.

- 2. The therapeutic agent for chronic obstructive pulmonary disease according to claim 1, wherein R_1 represents a hydrogen atom, or a linear or branched alkyl group having 1 to 10 carbon atoms.
- 3. The therapeutic agent for chronic obstructive pulmonary disease according to claim 1, wherein R_2 and R_3 each represents a hydrogen atom, an acyl group, a linear or

branched alkyl group having 1 to 10 carbon atoms, or a linear or branched alkenyl group having 2 to 10 carbon atoms.

- 4. The therapeutic agent for chronic obstructive pulmonary disease according to claim 1, wherein R_4 and R_5 each represents a hydrogen atom, an acyl group, a linear or branched alkyl group having 1 to 10 carbon atoms, a linear or branched alkenyl group having 2 to 10 carbon atoms, or an aralkyl group.
- 5. The therapeutic agent for chronic obstructive pulmonary disease according to claim 1, wherein R_1 represents a hydrogen atom, or a linear or branched alkyl group having 1 to 10 carbon atoms; R_2 and R_3 each represents a hydrogen atom, an acyl group, a linear or branched alkyl group having 1 to 10 carbon atoms, or a linear or branched alkenyl group having 2 to 10 carbon atoms; and R_4 and R_5 each represents a hydrogen atom, an acyl group, a linear or branched alkyl group having 1 to 10 carbon atoms, a linear or branched alkyl group having 1 to 10 carbon atoms, a linear or branched alkenyl group having 2 to 10 carbon atoms, or an aralkyl group.
- 6. The therapeutic agent for chronic obstructive pulmonary disease according to claim 5, wherein R_2 represents a hydrogen atom, and R_3 represents a linear or branched alkyl

group having 1 to 10 carbon atoms, or linear or branched alkenyl group having 2 to 10 carbon atoms.

- 7. The therapeutic agent for chronic obstructive pulmonary disease according to claim 5, wherein R_2 represents a linear or branched alkyl group having 1 to 10 carbon atoms, or a linear or branched alkenyl group having 2 to 10 carbon atoms, and R_3 represents a hydrogen atom.
- 8. The therapeutic agent for chronic obstructive pulmonary disease according to any one of claims 6 to 7, wherein R_4 represents a hydrogen atom, and R_5 represents a hydrogen atom, an acyl group, a linear or branched alkyl group having 1 to 10 carbon atoms, a linear or branched alkenyl group having 2 to 10 carbon atoms, or an aralkyl group.
- 9. The therapeutic agent for chronic obstructive pulmonary disease according to claim 8, wherein R_{5} represents an acyl group.
- 10. The therapeutic agent for chronic obstructive pulmonary disease according to claim 9, wherein R_5 represents an acyl group comprising a cinnamoyl group which may have a substituent.

- 11. The therapeutic agent for chronic obstructive pulmonary disease according to claim 10, wherein R_5 represents a 4-hydroxy-3-methoxycinnamoyl group or a 3,5-dimethoxy-4-hydroxycinnamoyl group.
- 12. The therapeutic agent for chronic obstructive pulmonary disease according to claim 1, wherein the chronic obstructive pulmonary disease is chronic bronchitis.
- 13. The therapeutic agent for chronic obstructive pulmonary disease according to claim 1, wherein the chronic obstructive pulmonary disease is pulmonary emphysema.
- 14. Use of the therapeutic agent for chronic obstructive pulmonary disease according to claim 1 for treating chronic obstructive pulmonary disease.
- 15. A method for treating chronic obstructive pulmonary disease, which comprises using the therapeutic agent for chronic obstructive pulmonary disease according to claim 1.
- 16. Use of at least one of a 7-aminoquinolinone derivative represented by the general formula (I);

$$R_5$$
 N
 O
 OR_2
 OR_3
 OR_2

wherein R_1 represents a hydrogen atom or an alkyl group; R_2 and R_3 each represents a group selected from a hydrogen atom, an acyl group, an alkyl group and an alkenyl group; and R_4 and R_5 each represents a group selected from a hydrogen atom, an acyl group, an alkyl group, an alkenyl group and an aralkyl group, and its physiologically acceptable salt, for preparing a therapeutic agent for chronic obstructive pulmonary disease.